Condition: Ovarian Cancer · Primary Peritoneal Cancer · Fallopian Tube Cancer · Sponsor: Nordic Society of Gynaecological Oncology - Clinical Trials Unit
This is a prospective observational multi-country, multi-center study of a large real-world cohort of first line (1L) epithelial ovarian cancer patients, exposed to standard of care (SOC) treatment stratified according to BRCA1/2 and HRD status.
This description comes directly from the study's public registry record.
Kristine Madsen, MD · 004535453311 · kristine.madsen.01@regionh.dk
Henriette W Hansen, MSc · 004535453311 · henriette.watson.hansen@regionh.dk
Always discuss trial participation with your own doctor first.
| Rigshospitalet | København Ø, Region Sjælland, Denmark | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05574673